GLPBio

Dauricine

Catalog No.: GC38182Purity:>98%
Dauricine is a bioactive alkaloid with anticancer properties extracted from Menispermum dauricum DC.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.


Dauricine
Cas No.: 524-17-4
10mM (in 1mL DMSO)In Stock
$77.00
1
1mgIn Stock
$21.00
1
5mgIn Stock
$56.00
1
10mgIn Stock
$98.00
1
20mgIn Stock
$161.00
1

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

Dauricine is a bioactive alkaloid with anticancer properties extracted from Menispermum dauricum DC. Dauricine inhibits tumor cell proliferation and induces apoptosis by suppressing signaling pathways such as Hedgehog, PI3K/Akt, and Src/STAT3[1-2]. Dauricine is applicable for research in various cancers and Alzheimer's disease[3-4].

In vitro, PC9-OR and H1975-OR osimertinib-resistant lung cancer cell lines were co-treated with Dauricine (0-100μM) and osimertinib. Dauricine induced ferroptosis in the cells, significantly inhibiting their viability[5]. A549, H1299, A427, and LLC lung adenocarcinoma cells were treated with Dauricine (5–20μM) for 24–48 hours. Dauricine significantly inhibited cell proliferation and migration, induced cell cycle arrest at the G0/G1 phase, increased intracellular reactive oxygen species (ROS) levels, downregulated Nrf2 expression, and ultimately triggered apoptosis[6].

In vivo, nude mice bearing BxPC-3 pancreatic cancer xenografts were treated with daily intraperitoneal injections of Dauricine (6mg/kg and 12mg/kg) for 21 days. Dauricine significantly inhibited tumor growth without markedly affecting the spleen index[7]. Ten-week-old female C57BL/6J mice were treated with intraperitoneal injections of Dauricine (2.5mg/kg; every two days) in combination with LPS (5mg/kg; once a week) for 3 weeks. Dauricine significantly alleviated LPS-induced inflammatory bone loss[8].

References:
[1] Chen KQ, Wang SZ, Lei HB, et al. Dauricine: Review of Pharmacological Activity. Drug Des Devel Ther. 2024 Sep 27;18:4371-4385.
[2] Li L, Dai S, Liu JY, et al. Antagonistic Effect and In Vitro Activity of Dauricine on Glucagon Receptor. J Nat Prod. 2022 Aug 26;85(8):2035-2043.
[3] Zhang X, Wang T, Miao Y, et al. Dauricine exhibits anti-inflammatory property against acute ulcerative colitis via the regulation of NF-κB pathway. Cell Biochem Funct. 2023 Aug;41(6):713-721.
[4] Wang L, Pu Z, Li M, et al. Antioxidative and antiapoptosis: Neuroprotective effects of dauricine in Alzheimer's disease models. Life Sci. 2020 Feb 15;243:117237.
[5] Men B, Chen Z, Ge H, et al. Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1. Cancer Sci. 2025 Aug;116(8):2256-2269.
[6] Yousuf W, Siddiqui NZ, Ali P, et al. Dauricine Impedes the Tumorigenesis of Lung Adenocarcinoma by Regulating Nrf2 and Reactive Oxygen Species. Cells. 2025 May 12;14(10):698.
[7] Zhang YB, Fei HX, Guo J, et al. Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway. Oncol Lett. 2019 Nov;18(5):4403-4414.
[8] Park HJ, Gholam Zadeh M, et al. Dauricine Protects from LPS-Induced Bone Loss via the ROS/PP2A/NF-κB Axis in Osteoclasts. Antioxidants (Basel). 2020 Jul 6;9(7):588.

Protocolo (Protocol)

Cell experiment [1]:

Cell lines

A549, H1299, A427, and Lewis Lung Carcinoma (LLC) cells (lung adenocarcinoma cell lines)

Preparation Method

A549 and H1299 cells were maintained in RPMI-1640 medium, A427 cells in Modified Eagles Medium (MEM), and LLC cells in Dulbecco's Modified Eagles Medium (DMEM), all supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C, 5% CO₂. Cells were treated with Dauricine (5–20μM) for 24-48 hours

Reaction Conditions

5–20μM; 24-48 hours.

Applications

Dauricine significantly inhibited the proliferation and migration of lung adenocarcinoma cells, induced cell cycle arrest at the G0/G1 phase, and markedly increased intracellular reactive oxygen species (ROS) levels. Dauricine also led to the downregulation of the redox regulator Nrf2 and altered the expression of apoptosis-related markers (decreased Bcl-2, increased BAX and cleaved Caspase 3).

Animal experiment [2]:

Animal models

10-week-old female C57BL/6J mice

Preparation Method

Mice were randomly assigned to four groups and treated via intraperitoneal injection for 3 weeks. Groups received: (1) vehicle control (PBS); (2) vehicle with Dauricine (2.5mg/kg, once every two days); (3) LPS (5mg/kg, once a week); (4) LPS with Dauricine.

Dosage form

2.5mg/kg; i.p.; once every two days for 3 weeks.

Applications

Co-treatment with Dauricine significantly prevented LPS-induced bone loss, as evidenced by increased bone mineral density (BMD), bone volume (BV/TV), and trabecular thickness (Tb.Th), and decreased trabecular separation (Tb.Sp). Dauricine also reduced the number of osteoclasts (OC.N/BS), lowered serum levels of the bone resorption marker CTX-1, the inflammatory marker MCP-1, and reactive oxygen species (ROS) elevated by LPS. Dauricine alone did not induce significant differences compared to the vehicle control.

References:
[1] Zhang YB, Fei HX, Guo J, et al. Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway. Oncol Lett. 2019 Nov;18(5):4403-4414.
[2] Park HJ, Gholam Zadeh M, et al. Dauricine Protects from LPS-Induced Bone Loss via the ROS/PP2A/NF-κB Axis in Osteoclasts. Antioxidants (Basel). 2020 Jul 6;9(7):588.

Propiedades químicas (Chemical Properties)

N.º CAS
524-17-4
SMILES
OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC=C(C[C@H]5N(C)CCC6=C5C=C(OC)C(OC)=C6)C=C4
Fórmula molecular
C38H44N2O6
Peso molecular
624.77
Solubilidad
DMSO : 100 mg/mL (160.06 mM; Need ultrasonic)
Almacenamiento
4°C, protect from light
Consejos generales
Seleccione un disolvente adecuado según los datos de solubilidad del producto. Una vez preparada, divida la solución madre en alícuotas para evitar ciclos repetidos de congelación y descongelación.
Utilice las soluciones madre en un plazo de 6 meses si se conservan a -80°C, o de 1 mes si se conservan a -20°C.
Para mejorar la solubilidad, caliente el tubo a 37°C y soníquelo durante un periodo adecuado.
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for Dauricine

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%